If you are referring to my post, that's definitely not what I was implying. Everything with regard to Merck's handling of Rida so far is pretty consistent with how they handle most of their programs (similar to Rida) from what I can tell. As much as Ariad shareholders would love for Merck to say lots of warm and fuzzy things about Rida, that's not in their agenda (nor in their best interest if they were possibly considering buying Ariad someday).
As far as the bio conference and earnings call, I seriously doubt they are going to announce anything we don't already know. It has been a little dry around here lately and it seems like we have some wishful thinking going on.
News 
Market Data 
Discover 
